Strengthening Physician Communication About HPV Vaccines
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02456077|
Recruitment Status : Completed
First Posted : May 28, 2015
Last Update Posted : June 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|HPV Immunization Status||Behavioral: Multimodal Vaccine Program||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||93582 participants|
|Intervention Model:||Parallel Assignment|
|Primary Purpose:||Health Services Research|
|Official Title:||Strengthening Physician Communication About HPV Vaccines|
|Actual Study Start Date :||February 1, 2015|
|Actual Primary Completion Date :||January 31, 2016|
|Actual Study Completion Date :||January 31, 2016|
Experimental: Intervention Practices
Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
Behavioral: Multimodal Vaccine Program
Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
No Intervention: Control Practices
Control offices will offer usual health care related to immunizations throughout the duration of the study.
- The percentage of adolescents who initiate the HPV vaccine series [ Time Frame: 1 year ]The percent of eligible patients presenting for care at intervention offices who receive one or more HPV vaccines (using administrative, Electronic Medical Records (EMR), and Colorado Immunization Information System (CIIS) immunization data), during the intervention year, compared to the percent in control offices.
- The percentage of adolescents who receive MCV4 vaccine [ Time Frame: 1 year ]The percent of eligible patients presenting for care at intervention offices who receive MCV4 vaccine (using administrative, EMR and CIIS immunization data) compared to the percent in control offices.
- The percentage of adolescents who receive Tdap vaccine [ Time Frame: 1 year ]The percentage of eligible patients presenting for care at intervention offices who receive Tetanus, Diphtheria, Pertussis (Tdap) vaccine (using administrative, EMR and CIIS immunization data) during the intervention year compared to the percent in control offices.
- Provider HPV vaccine recommendations [ Time Frame: 1 year ]The change in intervention providers' HPV vaccine communication practices compared to control providers' as measured by self-report prior to the intervention and after the intervention.
- Parents' experiences and preferences regarding provider communication about HPV vaccines [ Time Frame: 1 year ]The change in intervention parents' experiences and preferences regarding provider HPV vaccine communication compared to parents of adolescents attending control practices as measured by self report prior to the intervention and after the intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02456077
|United States, Colorado|
|University of Colorado Denver|
|Aurora, Colorado, United States, 80045|
|Principal Investigator:||Amanda Dempsey, MD, PhD, MPH||University of Colorado, Denver|